172 related articles for article (PubMed ID: 15073130)
1. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice.
Finkle D; Quan ZR; Asghari V; Kloss J; Ghaboosi N; Mai E; Wong WL; Hollingshead P; Schwall R; Koeppen H; Erickson S
Clin Cancer Res; 2004 Apr; 10(7):2499-511. PubMed ID: 15073130
[TBL] [Abstract][Full Text] [Related]
2. Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.
De Giovanni C; Nicoletti G; Quaglino E; Landuzzi L; Palladini A; Ianzano ML; Dall'Ora M; Grosso V; Ranieri D; Laranga R; Croci S; Amici A; Penichet ML; Iezzi M; Cavallo F; Nanni P; Lollini PL
Breast Cancer Res; 2014 Jan; 16(1):R10. PubMed ID: 24451168
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice.
Ladjemi MZ; Chardes T; Corgnac S; Garambois V; Morisseau S; Robert B; Bascoul-Mollevi C; Ait Arsa I; Jacot W; Pouget JP; Pelegrin A; Navarro-Teulon I
Breast Cancer Res; 2011 Feb; 13(1):R17. PubMed ID: 21294885
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
5. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors.
Romieu-Mourez R; Kim DW; Shin SM; Demicco EG; Landesman-Bollag E; Seldin DC; Cardiff RD; Sonenshein GE
Mol Cell Biol; 2003 Aug; 23(16):5738-54. PubMed ID: 12897145
[TBL] [Abstract][Full Text] [Related]
6. Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus.
Taha Z; Crupi MJF; Alluqmani N; Fareez F; Ng K; Sobh J; Lee E; Chen A; Thomson M; Spinelli MM; Ilkow CS; Bell JC; Arulanandam R; Diallo JS
Front Immunol; 2023; 14():1181014. PubMed ID: 37153626
[TBL] [Abstract][Full Text] [Related]
7. Suppression of Her2/Neu mammary tumor development in mda-7/IL-24 transgenic mice.
Li YJ; Liu G; Xia L; Xiao X; Liu JC; Menezes ME; Das SK; Emdad L; Sarkar D; Fisher PB; Archer MC; Zacksenhaus E; Ben-David Y
Oncotarget; 2015 Nov; 6(35):36943-54. PubMed ID: 26460950
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
[TBL] [Abstract][Full Text] [Related]
9. Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.
Provinciali M; Re F; Donnini A; Orlando F; Bartozzi B; Di Stasio G; Smorlesi A
Int J Cancer; 2005 May; 115(1):36-45. PubMed ID: 15688416
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of HER2 mRNA expression by RNA in situ hybridization in canine mammary gland tumors: Comparison with immunohistochemistry analysis.
Seung BJ; Cho SH; Kim SH; Lim HY; Sur JH
PLoS One; 2020; 15(2):e0229031. PubMed ID: 32059046
[TBL] [Abstract][Full Text] [Related]
11. Human HER2 overexpressing mouse breast cancer cell lines derived from MMTV.f.HuHER2 mice: characterization and use in a model of metastatic breast cancer.
Park S; Nedrow JR; Josefsson A; Sgouros G
Oncotarget; 2017 Sep; 8(40):68071-68082. PubMed ID: 28978097
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer.
Arteaga CL
Breast Cancer Res; 2003; 5(2):96-100. PubMed ID: 12631388
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis.
Amundadottir LT; Johnson MD; Merlino G; Smith GH; Dickson RB
Cell Growth Differ; 1995 Jun; 6(6):737-48. PubMed ID: 7669729
[TBL] [Abstract][Full Text] [Related]
16. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice.
Krane IM; Leder P
Oncogene; 1996 Apr; 12(8):1781-8. PubMed ID: 8622899
[TBL] [Abstract][Full Text] [Related]
17. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.
Campbell MJ; Wollish WS; Lobo M; Esserman LJ
In Vitro Cell Dev Biol Anim; 2002 Jun; 38(6):326-33. PubMed ID: 12513120
[TBL] [Abstract][Full Text] [Related]
18. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
Warburton C; Dragowska WH; Gelmon K; Chia S; Yan H; Masin D; Denyssevych T; Wallis AE; Bally MB
Clin Cancer Res; 2004 Apr; 10(7):2512-24. PubMed ID: 15073131
[TBL] [Abstract][Full Text] [Related]
19. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
20. Dual role of AP-2gamma in ErbB-2-induced mammary tumorigenesis.
Jäger R; Friedrichs N; Heim I; Büttner R; Schorle H
Breast Cancer Res Treat; 2005 Apr; 90(3):273-80. PubMed ID: 15830141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
